Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

Biotech ETFs offer diversified exposure to the sector, reducing investment risk. Investing in top biotech ETFs can be cost-effective due to their low expense ratios. Large biotech ETFs provide better ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to continue.

Over the past couple of years, the integration of Artificial Intelligence (AI) has ignited a revolutionary shift within the biotechnology industry. By mining massive biological datasets, AI has been ...

The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund launched on 06/23/2005. What Are ...

Shares of Moderna (MRNA) have surged sharply this week, drawing renewed attention to exchange traded funds with significant exposure to the U.S. pharmaceutical and biotechnology company. The stock ...

Fri, January 16, 2026 at 1:06 PM UTC Triple-leveraged ETFs aren't for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU) offers the ...

Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a rocky start to deliver some of the year’s most impressive gains. What began as a sector weighed down by tariff fears and ...

Investment giant KKR & Co. Inc. (NYSE: KKR) is advising investors to look past the crowded trades of the U.S. large-cap market for the next phase of growth. In its “High Grading” Outlook for 2026, the ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...